,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['trastuzumab', 'bcsm', 'breast', 'destiny-breast04']
encouraging results from destiny-breast04 presented by dr. shanu modi demonstrating improved overall survival (23.4 vs 16.8 mos) in her2-low #breastcancer using trastuzumab-deruxtecan (t-dxd) rather than physician's treatment choice. #asco22 #bcsm 
Mother of Warlords & Slayer of Cancers|Brst/Gyn #radonc @WeillCornell @nyphospital @nypbrooklyn | #globaloncology | #globalhealth|#MedEd|#gyncsm|#bcsm????????